{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:19:08Z","timestamp":1787689148505,"version":"build-2784847793"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":216,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Polyarteritis nodosa (PAN) is a rare vasculitis affecting predominately medium-sized vessels. Our evolving understanding of PAN, including the role of HBV and discovery of monogenic variants such as deficiency of adenosine deaminase 2 (DADA2), has resulted in idiopathic PAN becoming a very rare condition with an annual incidence of 0.6\u201319.9\/million. The investigative approach is to assess organ involvement and confirm the diagnosis either by imaging or biopsy. Conventional catheter angiography is being replaced by CT or MR angiography, which provide increasingly good resolution of the typical fusiform narrowing and aneurysm. ANCA-associated vasculitis (AAV) should be excluded. DADA2 is being more frequently identified as causing a PAN-like illness, especially in children; cases presenting in adulthood are now recognised. In children and most adults, genotyping for DADA2 should be undertaken. There are no high-quality randomised controlled trials of treatment in idiopathic PAN. Current approaches have been adapted from those used to treat other types of vasculitis. The five-factor score may be used to stratify patients to identify those needing intensive therapy with glucocorticoids combined with CYC. In order to reduce the burden of glucocorticoid toxicity, the ACR has advocated the use of immunosuppressive drugs in addition to steroids in those not initially receiving CYC. Unlike AAV, there appears to be little role for rituximab in the treatment of idiopathic PAN, although it is occasionally used as salvage therapy. HBV-associated PAN is treated with immunosuppression and antiviral therapy. There is reasonably good evidence to support the use of anti-TNF to treat DADA2.<\/jats:p>","DOI":"10.1093\/rap\/rkag083","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:36:48Z","timestamp":1784029008000},"source":"Crossref","is-referenced-by-count":0,"title":["Current and future advances in practice: polyarteritis nodosa and related vasculitides"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2846-4769","authenticated-orcid":false,"given":"Richard A","family":"Watts","sequence":"first","affiliation":[{"name":"Ipswich ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"2026082515211404900_rkag083-B1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/1529-0131(199908)12:4<294::AID-ART8>3.0.CO;2-6","article-title":"A history of early investigation in polyarteritis nodosa","volume":"12","author":"Matteson","year":"1999","journal-title":"Arthritis Care Res"},{"key":"2026082515211404900_rkag083-B2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/oxfordjournals.qjmed.a066514","article-title":"The kidney in periarteritis nodosa","volume":"17","author":"Davson","year":"1948","journal-title":"Q J Med"},{"key":"2026082515211404900_rkag083-B3","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/ajcp\/22.8.777","article-title":"Periarteritis nodosa; a critical review","volume":"22","author":"Zeek","year":"1952","journal-title":"Am J Clin Pathol"},{"key":"2026082515211404900_rkag083-B4","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/art.1780330805","article-title":"The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa","volume":"33","author":"Lightfoot","year":"1990","journal-title":"Arthritis Rheum"},{"key":"2026082515211404900_rkag083-B5","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/rheumatology\/kex075","article-title":"Are the 1990 American College of Rheumatology vasculitis classification criteria still valid?","volume":"56","author":"Seeliger","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2026082515211404900_rkag083-B6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides. Proposal of an international consensus conference","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2026082515211404900_rkag083-B7","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"Watts","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2026082515211404900_rkag083-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill Consensus Conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2026082515211404900_rkag083-B9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/sarh.2001.19958","article-title":"Polyarteritis nodosa in patients with familial mediterranean fever (FMF): a concomitant disease or a feature of FMF?","volume":"30","author":"Ozen","year":"2001","journal-title":"Semin Arthritis Rheum"},{"key":"2026082515211404900_rkag083-B10","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa1307361","article-title":"Early-onset stroke and vasculopathy associated with mutations in ADA2","volume":"370","author":"Zhou","year":"2014","journal-title":"N Engl J Med"},{"key":"2026082515211404900_rkag083-B11","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1056\/NEJMoa1307362","article-title":"Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy","volume":"370","author":"Navon Elkan","year":"2014","journal-title":"N Engl J Med"},{"key":"2026082515211404900_rkag083-B12","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N Engl J Med"},{"key":"2026082515211404900_rkag083-B13","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/art.1780390720","article-title":"Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis","volume":"39","author":"Watts","year":"1996","journal-title":"Arthritis Rheum"},{"key":"2026082515211404900_rkag083-B14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41584-021-00718-8","article-title":"Global epidemiology of vasculitis","volume":"18","author":"Watts","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2026082515211404900_rkag083-B15","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.5114\/aoms.2017.68407","article-title":"Polyarteritis nodosa: decreasing incidence in Poland","volume":"15","author":"Kanecki","year":"2019","journal-title":"Arch Med Sci"},{"key":"2026082515211404900_rkag083-B16","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1093\/rheumatology\/keaf052","article-title":"Incidence of ANCA-associated vasculitis and polyarteritis nodosa in Norfolk, UK, from 2011 to 2020","volume":"64","author":"Fordham","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026082515211404900_rkag083-B17","doi-asserted-by":"crossref","first-page":"103093","DOI":"10.1016\/j.jaut.2023.103093","article-title":"Clinical features and long-term outcomes of patients with systemic polyarteritis nodosa diagnosed since 2005: data from 196 patients","volume":"139","author":"Rohmer","year":"2023","journal-title":"J Autoimmun"},{"key":"2026082515211404900_rkag083-B18","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1093\/rheumatology\/keaf014","article-title":"The clinical characteristics and treatment outcomes of patients with systemic polyarteritis nodosa: a single-centre study from India","volume":"64","author":"Jha","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026082515211404900_rkag083-B19","doi-asserted-by":"crossref","first-page":"i79","DOI":"10.1093\/rheumatology\/keae649","article-title":"Idiopathic polyarteritis nodosa \u2013 does it still exist? Viewpoint 1: as our knowledge makes progress, idiopathic polyarteritis nodosa is fading away","volume":"64","author":"Watts","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026082515211404900_rkag083-B20","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/art.42817","article-title":"Clinical characteristics and outcomes of polyarteritis nodosa: an international study","volume":"76","author":"Karadag","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026082515211404900_rkag083-B21","first-page":"176","article-title":"Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial","volume":"35(Suppl 103)","author":"Samson","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2026082515211404900_rkag083-B22","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/art.27240","article-title":"Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group database","volume":"62","author":"Pagnoux","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2026082515211404900_rkag083-B23","doi-asserted-by":"publisher","first-page":"keaf685","DOI":"10.1093\/RHEUMATOLOGY\/KEAF685","article-title":"Polyarteritis nodosa associated with VEXAS syndrome and chronic myelomonocytic leukemia: a case\u2013control study","volume":"65","author":"Cioni","year":"2026","journal-title":"Rheumatology (Oxford)."},{"key":"2026082515211404900_rkag083-B24","doi-asserted-by":"crossref","first-page":"e15377","DOI":"10.1111\/1756-185X.15377","article-title":"Long-term follow-up of anti-TNF treatment in adult and pediatric DADA2 patients: Insights from real-world data","volume":"27","author":"Ayan","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"2026082515211404900_rkag083-B25","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1093\/rheumatology\/keaf293","article-title":"Clinical features in VEXAS syndrome: a systematic review","volume":"64","author":"Al-Hakim","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026082515211404900_rkag083-B26","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/art.41776","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of polyarteritis nodosa","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026082515211404900_rkag083-B27","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/rheumatology\/keab591","article-title":"Fluorodeoxyglucose positron emission tomography-computed tomography findings in a first series of 10 patients with polyarteritis nodosa","volume":"61","author":"Fagart","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026082515211404900_rkag083-B28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00005792-199601000-00003","article-title":"Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients","volume":"75","author":"Guillevin","year":"1996","journal-title":"Medicine"},{"key":"2026082515211404900_rkag083-B29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/rheumatology\/keac332","article-title":"Use of biologics to treat relapsing and\/or refractory polyarteritis nodosa: data from a European collaborative study","volume":"62","author":"Hadjadj","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026082515211404900_rkag083-B30","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/J.JAAD.2025.11.014","article-title":"Tocilizumab for refractory and\/or relapsing polyarteritis nodosa","volume":"94","author":"Cottu","year":"2026","journal-title":"J Am Acad Dermatol."},{"key":"2026082515211404900_rkag083-B31","doi-asserted-by":"crossref","first-page":"omea199","DOI":"10.1093\/omcr\/omae199","article-title":"Efficacy of upadacitinib in refractory polyarteritis nodosa: a case report","volume":"2","author":"Nakabayashi","year":"2025","journal-title":"Oxf Med Case Rep"},{"key":"2026082515211404900_rkag083-B32","doi-asserted-by":"crossref","first-page":"2417965","DOI":"10.1080\/09546634.2024.2417965","article-title":"Successful treatment of cutaneous polyarteritis nodosa with baricitinib","volume":"35","author":"Zhou","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"2026082515211404900_rkag083-B33","doi-asserted-by":"crossref","first-page":"1644404","DOI":"10.3389\/fimmu.2025.1644404","article-title":"VEXAS: a review of current understandings and emerging treatment strategies","volume":"16","author":"Holden","year":"2025","journal-title":"Front Immunol"},{"key":"2026082515211404900_rkag083-B34","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(25)02164-6","article-title":"VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies","volume":"407","author":"Groarke","year":"2026","journal-title":"Lancet"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/10\/3\/rkag083\/70500425\/rkag083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/10\/3\/rkag083\/70500425\/rkag083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:21:23Z","timestamp":1787685683000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkag083\/8752913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6,15]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkag083","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"rkag083"}}